TVMR With the INNOVALVE System Trial - Early Feasibility Study

NCT ID: NCT04919980

Last Updated: 2026-01-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

65 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-01

Study Completion Date

2031-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to evaluate the safety and performance of the INNOVALVE system

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a multi-center, First-In-Human, prospective, single arm early feasibility study to evaluate the safety and performance of the INNOVALVE system

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mitral Valve Regurgitation (Degenerative or Functional)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

MV replacement with INNOVALVE system

Group Type EXPERIMENTAL

INNOVALVE system

Intervention Type DEVICE

INNOVALVE system

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

INNOVALVE system

INNOVALVE system

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinically significant, symptomatic mitral regurgitation
* High risk for open-heart surgery
* Meets anatomical criteria

Exclusion Criteria

* Unsuitable anatomy
* Patient is inoperable
* EF\<25%
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Edwards Lifesciences

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chet Rihal

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cedars-Sinai

Los Angeles, California, United States

Site Status RECRUITING

Naples Comprehensive Health

Naples, Florida, United States

Site Status RECRUITING

Piedmont Heart Institute

Atlanta, Georgia, United States

Site Status RECRUITING

Northwestern

Chicago, Illinois, United States

Site Status RECRUITING

University of Michigan Hospital and Health Systems

Ann Arbor, Michigan, United States

Site Status RECRUITING

Mayo Clinic

Rochester, Minnesota, United States

Site Status RECRUITING

Morristown Medical Center

Morristown, New Jersey, United States

Site Status RECRUITING

Northwell Health

Manhasset, New York, United States

Site Status RECRUITING

Cornell

New York, New York, United States

Site Status WITHDRAWN

NewYork-Presbyterian / Columbia University

New York, New York, United States

Site Status RECRUITING

Cleveland Clinic

Cleveland, Ohio, United States

Site Status RECRUITING

OhioHealth Research Institute

Columbus, Ohio, United States

Site Status RECRUITING

Oregon Health & Science Universtiy

Portland, Oregon, United States

Site Status RECRUITING

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status RECRUITING

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status RECRUITING

Ascension Saint Thomas

Nashville, Tennessee, United States

Site Status RECRUITING

Swedish Medical Center

Seattle, Washington, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

TMTT Clinical

Role: CONTACT

(949) 250-2500

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mitch Gheorghiu

Role: primary

310-407-9553

Kathy Byrd

Role: primary

239-624-8113

Jennifer Bolivar Aldana

Role: primary

770-846-0344

BCVI Clinical Trials Unit

Role: primary

312-926-4000

Keoni Fordham

Role: primary

734-763-6551

Carl Griffin

Role: primary

Catherine Van Zile

Role: primary

973-971-5951

Samantha Annunziato

Role: primary

516-600-1475

Treena Williams

Role: primary

Emily Tylicki

Role: primary

216-444-6950

Katy Monnin

Role: primary

614-566-5768

Emmanuel Mills, MD

Role: primary

503-494-3925

Kelli Cook

Role: primary

215-459-4478

Kathy Adams

Role: primary

615-322-9845

Natalie Jackson

Role: backup

615-343-1782

Emily Normandin

Role: primary

615-222-3852

Zaw Nu Dan

Role: primary

206-215-2431

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-13

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

TTVR Early Feasibility Study
NCT04433065 RECRUITING NA
Sutra Hemi-valve First-in-Human Study
NCT06552689 RECRUITING NA
Capstan Medical TMVR Study: FIH
NCT06600191 RECRUITING NA